Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | RYR2 | Q92736 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.38 |
| ▸ | LIPE | Q05469 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22350718 | 0.79 | HTR1A (0.69) | HTR1APOLBKDM4EALDH1A1KMT2A | |
| SCHEMBL12928358 | 0.79 | HTR1A (0.69) | HTR1APOLBKDM4EALDH1A1KMT2A | |
| SCHEMBL1858027 | 0.77 | HTR1A (0.67) | HTR1APOLBKDM4EALDH1A1KMT2A | |
| SCHEMBL26614873 | 0.77 | MAPT (0.47) | ALDH1A1KMT2ATSHRMAPTNPSR1 | |
| Diethylcarbamazine SCHEMBL67289 | 0.75 | HTR1A (1.00) | HTR1APOLBKDM4EALDH1A1KMT2A | |
| Diethylcarbamazine SCHEMBL1819685 | 0.75 | HTR1A (1.00) | HTR1APOLBKDM4EALDH1A1KMT2A | |
| Diethylcarbamazine SCHEMBL10412471 | 0.73 | HTR1A (0.96) | HTR1APOLBKDM4EALDH1A1KMT2A | |
| SCHEMBL2420417 | 0.73 | HTR1A (0.62) | HTR1APOLBKDM4EALDH1A1KMT2A | |
| SCHEMBL4612540 | 0.73 | HTR1A (0.62) | HTR1APOLBKDM4EALDH1A1KMT2A | |
| SCHEMBL11508763 | 0.73 | HTR1A (0.68) | HTR1APOLBKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564204-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | The University of Tokyo (JP) | 2019-11-06 | — | — | EP | disclosed |
| EP-3045445-B1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | UNIV TOKYO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2606021-B1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | UNIV TOKYO (JP) | 2019-07-31 | — | — | EP | disclosed |
| EP-3045445-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | THE UNIVERSITY OF TOKYO (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-9359279-B2 | Treatment of cancer, inflammatory disease, and autoimmune disease | ALLIANZ PHARMASCIENCE LTD. (TW) | 2016-06-07 | — | — | US | disclosed |
| US-20140371177-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASE, AND AUTOIMMUNE DISEASE | ALLIANZ PHARMASCIENCE LTD. (TW) | 2014-12-18 | — | — | US | disclosed |
| US-8822732-B2 | 1,5-diphenyl-penta-1,4-dien-3-one compounds | ANDROSCIENCE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| EP-2606021-A2 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | The University of Tokyo (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| WO-2012024282-A2 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | SHIH CHARLES C-Y (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | ALLIANZ PHARMASCIENCE LTD. (TW) | 2012-02-23 | — | — | US | disclosed |
| EP-2233479-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | Liverpool School of Tropical Medicine (GB) | 2010-09-29 | — | — | EP | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| WO-2008038030-A2 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | PDCD5, IL5, MALT1 | HTR1A 1488/4885POLB 1655/4885KDM4E 1325/4885 |
| US-20140371177-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASE, AND AUTOIMMUNE DISEASE | PHOSPHO1, SELENOI, CD2 | HTR1A 4292/4885POLB 1550/4885KDM4E 433/4885 |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | NR1H2, NR1H3, NR1I2 | HTR1A 1950/4885POLB 2091/4885KDM4E 2301/4885 |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | NR1H3, NR1H2, NR1I2 | HTR1A 1041/4885POLB 1923/4885KDM4E 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.